I often think of the first couple of years after a drug has been approved as its guinea-pig period. After all, even the most careful clinical trials of a new medication usually involve just a few thousand patients. So, in the beginning, only a drug's most common side effects are known. But once a pharmaceutical clears the Food and Drug Administration's review process, hundreds of thousands, if not millions, of people start taking it. That's when you get a better idea of the true rate of complications, as well as any untoward interactions with other drugs.
Consider what happened with Rezulin,...
To continue reading:
or
Log-In
